KCM
PCVX icon

Kennedy Capital Management’s Vaxcyte PCVX Stock Holding History

Kennedy Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,671
Closed -$217K – 595
2025
Q2 		$217K Buy
6,671
+165
+3% +$5.41K 0.01% 565
2025
Q1 		$246K Sell
6,506
-10,020
-61% -$801K 0.01% 620
2024
Q4 		$1.35M Buy
+16,526
New +$1.64M 0.03% 563
2024
Q3 		– Sell
-6,252
Closed -$472K – 720
2024
Q2 		$472K Buy
6,252
+2,482
+66% +$169K 0.01% 639
2024
Q1 		$258K Buy
+3,770
New +$261K 0.01% 689

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Kennedy Capital Management's PCVX Position: Q3 2025 in Review

Kennedy Capital Management sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 6,671 shares — an estimated $217K sold.

Kennedy Capital Management first reported a position in PCVX in Q1 2024 and held it in 5 quarters. The position peaked at $1.35M in Q4 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Kennedy Capital Management reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 6,671 Vaxcyte shares in Q3 2025, an estimated $217K.
  • Kennedy Capital Management first reported a position in Vaxcyte in Q1 2024 and held it in 5 quarters.
  • Kennedy Capital Management's Vaxcyte position peaked at $1.35M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Kennedy Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.